Snapshot from Sep 19, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical breakthrough

Estriol-Progesterone Therapy Eases Menopause Brain Fog

Analysis based on 7 articles · First reported Sep 01, 2026 · Last updated Sep 01, 2026

Sentiment
30
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The positive results could boost interest in hormone-based therapies for menopause-related cognitive symptoms, potentially benefiting companies like CleopatraRX that hold related patents. However, the small, uncontrolled nature of the study limits immediate market impact, and FDA approval remains a key hurdle.

Pharmaceuticals Healthcare Biotechnology

A small pilot study by UCLA Health, published in Scientific Reports on September 1, 2026, found that a combination hormone therapy of estriol and progesterone significantly improved self-reported cognitive symptoms ('brain fog') in 20 menopausal women after 12 months of treatment. Improvements were reported in concentration, working memory, processing speed, verbal memory, and problem-solving. Preclinical experiments in midlife female mice supported these findings, showing reduced hippocampal pathology and improved cognitive performance. The treatment, marketed as PearlPAK by CleopatraRX, is not yet FDA-approved and is currently available only as a compounded medication in the U.S. The study's senior author, Dr. Rhonda Voskuhl, is an inventor on UCLA patents related to the treatment and serves as a medical advisor to CleopatraRX. The authors caution that the results are preliminary and require confirmation in larger, placebo-controlled trials.

70 Rhonda Voskuhl invented treatment CleopatraRX
per
Senior author and inventor of the treatment; her involvement lends credibility and could lead to further research and commercialization opportunities.
Importance 85.0 Sentiment 50.0
priv
Licenses the UCLA patents and markets the treatment as PearlPAK; positive study results could increase commercial prospects, though FDA approval is still needed.
Importance 70.0 Sentiment 60.0
govactor
Regulatory body that has not approved estriol; the study may inform future regulatory decisions but no immediate action is expected.
Importance 60.0 Sentiment 0.0
oth
Affiliated with the study's authors; contributes to the institution's research reputation.
Importance 40.0 Sentiment 20.0
priv
Parent publisher of Scientific Reports; publication adds prestige but no direct financial impact.
Importance 30.0 Sentiment 10.0
per
Lead author of the study; her work is central to the findings, potentially advancing her career.
Importance 30.0 Sentiment 10.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.